Kezar Life Sciences reports Q2 2024 net loss $21.5M; stops KZR-261 Phase 1, revises PORTOLA data to H1 2025

Kezar Life Sciences, Inc.

2024-Q2 EPS reported -$0.59

Net loss $21.5M ($0.30 per share) vs $24.3M ($0.34) in Q2 2023; cash $164.2M (down from $201.4M Dec 2023).
Enrollment completed in PORTOLA Phase 2a for autoimmune hepatitis; topline data expected first half 2025 (revised from prior guidance).
Enrollment stopped in KZR-261 Phase 1 for refractory solid tumors; no objective responses observed, resources redirected to zetomipzomib.
PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.
R&D expenses down $4.7M to $16.3M vs $21.0M; restructuring charge $1.5M related to office space impairment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.